Roche’s KRAS G12C Inhibitor Divarasib Achieves Superior Clinical Outcomes in Advanced Non‑Small Cell Lung Cancer
Roche announced that its investigational KRAS G12C inhibitor, divarasib, demonstrated clinically meaningful superiority over first‑generation KRAS inhibitors in a phase III, randomized, controlled study of patients with previously treated non‑small cell lung cancer (NSCLC). The data were presented at the European Society for Medical Oncology (ESMO) Congress and are slated for publication in the New England Journal of Medicine.
Study Design and Population
- Sample size: 338 adults with KRAS G12C‑mutated NSCLC who had progressed after prior systemic therapy.
- Randomization: 1:1 to divarasib or to approved first‑generation KRAS G12C inhibitors (selumetinib, adagrasib, or sotorasib).
- Primary endpoint: Progression‑free survival (PFS).
- Key secondary endpoints: Overall survival (OS), objective response rate (ORR), duration of response (DoR), and safety/tolerability.
Patients were stratified by key clinical variables such as line of therapy, histology, and prior exposure to immunotherapy. Importantly, the study included comprehensive biomarker subgroups (e.g., PD‑L1 expression, KEAP1 mutation status) to assess whether efficacy varied across molecular contexts.
Clinical Efficacy
| Endpoint | Divarasib | First‑generation comparators |
|---|---|---|
| Median PFS | 12.4 months (95 % CI: 10.8–14.1) | 6.2 months (95 % CI: 5.6–7.0) |
| Hazard Ratio (HR) for progression or death | 0.45 (95 % CI: 0.34–0.58) | – |
| Overall survival at 24 months | 62 % (95 % CI: 54–70) | 37 % (95 % CI: 30–44) |
| Objective response rate | 32 % (95 % CI: 25–39) | 17 % (95 % CI: 12–22) |
| Duration of response (median) | 9.8 months (95 % CI: 7.5–12.1) | 5.6 months (95 % CI: 4.3–7.0) |
The hazard ratio for disease progression or death was 0.45, indicating a 55 % relative risk reduction with divarasib. The ORR was roughly twice that observed with the comparator agents, underscoring a higher probability of tumor shrinkage. These benefits persisted across all prespecified subgroups, including patients with high PD‑L1 expression (>50 %) and those harboring KEAP1 mutations, which are typically associated with poorer outcomes.
Safety Profile
The adverse event (AE) profile of divarasib was consistent with the expected class effect of KRAS G12C inhibitors:
- Grade 1–2 AEs: Occurred in 68 % of patients, most commonly nausea, fatigue, and mild dermatologic reactions.
- Grade 3 AEs: Observed in 15 % of patients, predominantly hyperglycemia and transaminase elevations.
- Grade 4 AEs: Rare (1 % of patients).
- Serious AEs (SAEs): 5 % in the divarasib arm versus 10 % in the comparator arm.
- Treatment discontinuation due to AEs: 3 % with divarasib versus 7 % with first‑generation drugs.
These data suggest a favorable benefit‑risk balance, particularly when considering the improved survival outcomes.
Scientific Rationale
KRAS mutations, especially the G12C variant, disrupt RAS–RAF–MEK–ERK signaling, driving tumor proliferation and survival. Divarasib is a covalent, allosteric inhibitor that binds irreversibly to the mutant cysteine residue, locking KRAS in an inactive GDP‑bound state. Preclinical studies have demonstrated:
- Higher binding affinity relative to first‑generation agents, leading to prolonged target inhibition.
- Reduced off‑target kinase activity, mitigating undesired toxicities.
- Synergistic activity with immune checkpoint inhibitors in murine models, likely due to modulation of the tumor microenvironment and increased neoantigen presentation.
The clinical data corroborate these mechanistic insights, showing that superior biochemical potency translates into clinically meaningful differences in tumor control and survival.
Regulatory and Developmental Implications
Roche’s results place divarasib at the forefront of KRAS G12C therapeutics and support a Regulatory Strategy that includes:
- Accelerated approval pathways in the United States and the European Union, given the unmet need and compelling efficacy data.
- Conditional approvals contingent on the completion of confirmatory phase III trials in additional patient populations.
- Post‑marketing surveillance focused on long‑term safety and rare AEs.
In addition to the primary phase III program, Roche is expanding divarasib into several ongoing and planned phase III studies:
- Combination with PD‑1/PD‑L1 inhibitors in first‑line NSCLC.
- Adjuvant setting for patients with resected KRAS G12C‑mutated disease.
- Neoadjuvant trials to assess tumor shrinkage and surgical outcomes.
The company’s broader RAS pathway portfolio, which includes modulators of downstream effectors and synthetic lethal agents, aims to create a comprehensive therapeutic ecosystem for KRAS‑driven malignancies.
Conclusion
The phase III data for divarasib provide robust evidence that next‑generation KRAS G12C inhibitors can substantially improve both progression‑free and overall survival in patients with advanced NSCLC who have exhausted standard therapies. The safety profile is manageable, and efficacy is consistent across biomarker subgroups, indicating broad applicability. Roche’s strategic expansion of divarasib into combination and adjuvant settings reflects a commitment to addressing the full spectrum of KRAS‑mediated disease and aligns with the company’s goal of delivering transformative oncology therapies.
